China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A

China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A

SSSE:600750
23.57
CNY
+0.25
(+1.07%)
1.48EPS
16.85P/E
14.32BMarket Cap
Mar 19Next Earn
China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A
SSE:600750
(Shanghai Stock Exchange)

Recent

price

23.57

P/E

ratio

16.85

div

yld

4.40%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.11
4.04
4.86
4.22
4.43
4.11
2.49
2.76
2.8
3.91
3.87
4.55
6.17
7.22
7.03
6.65
6.28
Revenue per Share
0.42
0.35
0.34
0.26
0.41
0.58
0.6
0.66
0.75
0.74
0.75
0.8
0.95
1.14
1.25
1.43
1.34
Basic EPS, GAAP
0.13
-0.12
- -
0.07
0.4
0.71
1
-0.01
0.58
0.9
0.9
1.15
1.07
1.31
0.79
1.09
- -
Free Cash Flow per Basic Share
0.16
0.16
0.17
0.19
0.19
0.19
0.2
0.19
0.22
0.23
0.26
0.5
1.16
1.3
1.22
1.23
1.04
Dividend per Share
2.65
2.86
3.06
3.18
3.3
3.74
4.15
4.63
5.15
5.65
6.15
6.35
6.2
6.21
6.14
6.34
5.93
Book Value per Share
2.06
2.24
2.47
2.61
2.7
3.18
3.62
4.11
4.65
5.06
5.53
5.66
5.53
5.5
5.44
5.59
5.18
Tangible Book Value per Share
623
655
657
658
639
632
628
633
627
626
632
632
630
630
631
634
629
Basic Weighted Avg Shares
2,564
2,647
3,192
2,778
2,834
2,597
1,562
1,747
1,755
2,449
2,441
2,874
3,885
4,553
4,435
4,220
3,948
Sales/Revenue/Turnover
12.78
9.74
8.99
7.14
14.59
18.57
27.92
26.9
29.75
21.32
23.78
19.51
17.34
19.77
21.74
26.5
25.47
Operating Margin (%)
70
67
76
94
83
68
66
63
73
113
113
115
122
126
137
151
- -
Depreciation Expense
261
228
225
172
265
367
380
418
470
464
474
506
598
719
788
907
841
Net Income, GAAP
13.71
16.19
15.76
17.19
20.23
16.39
14.39
11.56
14.18
15.29
15.37
14.79
14.19
14.09
16.1
18.57
15.28
Effective Tax Rate (%)
10.19
8.61
7.06
6.2
9.34
14.13
24.31
23.92
26.79
18.93
19.4
17.6
15.4
15.78
17.77
21.49
21.29
Profit Margin (%)
810
784
1,281
1,389
1,407
1,046
1,322
1,638
1,796
2,313
2,674
2,748
2,377
924
716
1,523
857
Working Capital
- -
- -
525
497
498
- -
- -
70
50
- -
- -
3
1
1
- -
1
4
LT Debt
1,779
1,918
2,053
2,133
2,133
2,355
2,616
2,915
3,244
3,924
4,251
4,582
4,508
4,629
4,472
4,703
4,505
Total Equity
15.82
11.14
9.2
6.23
9.84
13.98
15.02
14.93
14.64
13.03
11.76
11.98
13.97
16.9
18.62
20.93
- -
Return on Invested Capital (%)
16.33
11.42
9.94
7.39
10.86
15.34
15.27
14.85
14.93
12.37
11.22
10.94
12.18
14.36
15.76
18.03
- -
Return on Capital (%)
18.94
12.66
11.65
8.44
12.74
16.56
15.28
15.11
15.27
13.63
12.74
12.83
15.13
18.4
20.28
23
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
6
LT Borrowings
- -
- -
4
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
636
636
636
Market Capitalization
16,984
14,028
14,320

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,472
2,968
2,700
Cash, Cash Equivalents & STI
938
887
706
Accounts Receivable, Net
488
422
385
Inventories
408
408
444
Total Current Liabilities
1,870
1,768
1,843
Payables & Accruals
- -
- -
- -
ST Debt
1
1
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.38%
2.13%
5.18%
Free Cash Flow
-450.27%
8.46%
39.32%
Net Income, GAAP
9.67%
13.97%
15.03%
Sales/Revenue/Turnover
7.43%
12.53%
-4.87%
Total Cash Common Dividend
26.43%
46.49%
1.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,274
945
799
1,464
4,435
2025
1,184
957
- -
1,286
4,220
2026
1,036
896
730
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.35
0.23
0.25
1.25
2025
0.45
0.38
- -
0.36
1.43
2026
0.46
0.32
0.2
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.51
1.22
2025
- -
- -
- -
0.5
1.23
2026
- -
- -
0.53
- -
- -
Business
Jiang Zhong Pharmaceutical Co.,Ltd Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) is a China-based company principally engaged in the research, development, production, and sale of Chinese patent medicines, over-the-counter (OTC) pharmaceuticals, health foods, and prescription drugs. The company offers a broad portfolio of OTC products covering spleen and stomach health such as stomach health tablets and Jianweixiaoshi tablets; intestinal tract care including lactic acid bacterin tablets/granules and bifidobacteria trifecta enteric capsules (Befeida); anorectal treatments; throat, cough, and asthma remedies like compound fresh bamboo extract and chuanbei loquat capsules; supplements and minerals such as multi-dimensional element tablets; and chronic disease management options. Its health consumer products encompass high-end nourishment, rehabilitation nutrition, gastrointestinal health, liver and gallbladder protection like pure liver tablets, dietary nutrition, basic vitamins, personal care essential oils, and probiotics; prescription drugs target heart and brain vascular conditions, chronic respiratory diseases, including cloprocaine hydrochloride injections and rabeprazole sodium enteric tablets; products are marketed under brands including Jiangzhong, Lihuo, Chuyuan, Shenlingcao, Yang Jisheng, and Songhai, primarily serving domestic markets in mainland China with headquarters in Nanchang, Jiangxi Province, where it was founded in 1969 and listed on the Shanghai Stock Exchange in 1996 as a subsidiary of China Resources Jiangzhong Pharmaceutical Group Co., Ltd. Recent developments include the controlling shareholder China Resources Jiangzhong cumulatively increasing its stake by 0.45% to 43.14% through open market purchases totaling RMB 61.29 million as of October 2025, further purchases adding 0.15% for RMB 19.75 million by April 2025, and agreements to acquire a 51% stake in Jiangxi Jiang Zhong Chinese Medicine Pieces Co., Ltd. as well as a proposed 70% equity interest in Jingcheng Huizhong Medicine; the company also earned recognitions such as inclusion in the Ministry of Industry and Information Technology's first batch of exemplary smart factories and digital navigation enterprise cases in early 2025, alongside stable 2025 performance with Q3 revenue of RMB 792 million despite a 6.3% yearly decline, and a net profit rise of 5.5% to RMB 683 million for the first three quarters.